148 related articles for article (PubMed ID: 29675601)
1. Asymptotic analysis of a TMDD model: when a reaction contributes to the destruction of its product.
Michalaki LI; Goussis DA
J Math Biol; 2018 Sep; 77(3):821-855. PubMed ID: 29675601
[TBL] [Abstract][Full Text] [Related]
2. Asymptotic Analysis of a Target-Mediated Drug Disposition Model: Algorithmic and Traditional Approaches.
Patsatzis DG; Maris DT; Goussis DA
Bull Math Biol; 2016 Jun; 78(6):1121-61. PubMed ID: 27271122
[TBL] [Abstract][Full Text] [Related]
3. The computation of biomarkers in pharmacokinetics with the aid of singular perturbation methods.
Ma J; Keener JP
J Math Biol; 2018 Nov; 77(5):1407-1430. PubMed ID: 30056506
[TBL] [Abstract][Full Text] [Related]
4. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
Cao Y; Jusko WJ
J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917
[TBL] [Abstract][Full Text] [Related]
5. Approximations of the target-mediated drug disposition model and identifiability of model parameters.
Gibiansky L; Gibiansky E; Kakkar T; Ma P
J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):573-91. PubMed ID: 19005743
[TBL] [Abstract][Full Text] [Related]
6. General Pharmacokinetic Features of Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Simulation-Based Study.
Bach T; Jiang Y; Zhang X; An G
J Clin Pharmacol; 2019 Mar; 59(3):394-405. PubMed ID: 30387863
[TBL] [Abstract][Full Text] [Related]
7. Target-mediated drug disposition model for drugs that bind to more than one target.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
[TBL] [Abstract][Full Text] [Related]
8. Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds.
An G
J Clin Pharmacol; 2020 Feb; 60(2):149-163. PubMed ID: 31793004
[TBL] [Abstract][Full Text] [Related]
9. Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Minireview.
An G
J Clin Pharmacol; 2017 Feb; 57(2):137-150. PubMed ID: 27489162
[TBL] [Abstract][Full Text] [Related]
10. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):341-51. PubMed ID: 19578985
[TBL] [Abstract][Full Text] [Related]
11. Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):463-475. PubMed ID: 28725976
[TBL] [Abstract][Full Text] [Related]
12. Target-mediated drug disposition and dynamics.
Mager DE
Biochem Pharmacol; 2006 Jun; 72(1):1-10. PubMed ID: 16469301
[TBL] [Abstract][Full Text] [Related]
13. Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies.
Djebli N; Martinez JM; Lohan L; Khier S; Brunet A; Hurbin F; Fabre D
Clin Pharmacokinet; 2017 Oct; 56(10):1155-1171. PubMed ID: 28063030
[TBL] [Abstract][Full Text] [Related]
14. Geometric singular perturbation analysis of a dynamical target mediated drug disposition model.
Kristiansen KU
J Math Biol; 2019 Jul; 79(1):187-222. PubMed ID: 30972439
[TBL] [Abstract][Full Text] [Related]
15. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition.
Mager DE; Krzyzanski W
Pharm Res; 2005 Oct; 22(10):1589-96. PubMed ID: 16180117
[TBL] [Abstract][Full Text] [Related]
16. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.
Yan X; Mager DE; Krzyzanski W
J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):25-47. PubMed ID: 20012173
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of target-mediated drug disposition.
Peletier LA; Gabrielsson J
Eur J Pharm Sci; 2009 Dec; 38(5):445-64. PubMed ID: 19786099
[TBL] [Abstract][Full Text] [Related]
18. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.
Gibiansky L; Gibiansky E
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):803-12. PubMed ID: 19505189
[TBL] [Abstract][Full Text] [Related]
19. Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations.
Grimm HP
J Pharmacokinet Pharmacodyn; 2009 Oct; 36(5):407-20. PubMed ID: 19728050
[TBL] [Abstract][Full Text] [Related]
20. A Pharmacometrics Model to Characterize a New Type of Target-Mediated Drug Disposition (TMDD) - Nonlinear Pharmacokinetics of Small-Molecule PF-07059013 Mediated By Its High-capacity Pharmacological Target Hemoglobin With Positive Cooperative Binding.
Xu M; An G
AAPS J; 2023 Apr; 25(3):41. PubMed ID: 37055588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
